Perspectivas 2026 de Dong-A ST (KOSPI 170900). Análisis del biosimilar de ustekinumab IMULDOSA con aprobaciones en EE. UU. y Europa, la licencia con Intas y Accord, la hormona de crecimiento Growtropin, el pipeline de diabetes y obesidad, la presión de precios de medicamentos en Corea y su comparación con Celltrion, Samsung Bioepis, Chong Kun Dang y Yuhan.
Dong-A ST (KOSPI 170900) 2026 stock outlook. A deep look at the IMULDOSA ustekinumab biosimilar with US and EU approvals, Intas and Accord licensing, the Growtropin growth-hormone franchise, diabetes and obesity pipeline, Korean drug-price pressure, and how it stacks up against Celltrion, Samsung Bioepis, Chong Kun Dang and Yuhan.
Prestige Biopharma (KOSPI 950210) 2026 stock analysis: the Tuznue trastuzumab biosimilar commercialization path and the PBP1510 (ulenistamab) pancreatic-cancer antibody's clinical and regulatory milestones, dilution risk from ongoing losses and financing, the quirks of a Singapore-domiciled foreign company listed on KOSPI, and why this is a high-risk, pipeline-driven biotech.
REGN Regeneron stock outlook 2026. Dupixent global sales hit $4.9B in Q1 2026 (+33%), Eylea HD biosimilar transition, Lynozyfic FDA approval July 2025, Libtayo oncology surge, three-scenario valuation for US investors.